Search
Capmatinib
go.drugbank.com/drugs/DB11791ApprovedInvestigationalCapmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesNiraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigationalNiraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First appr...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 InducersBictegravir
go.drugbank.com/drugs/DB11799ApprovedInvestigationalBictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesErtugliflozin
go.drugbank.com/drugs/DB11827ApprovedInvestigationalErtugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 20...
Categories: P-glycoprotein substratesPrulifloxacin
go.drugbank.com/drugs/DB11892InvestigationalPrulifloxacin has been investigated for the treatment of Urinary Tract Infection.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsIlaprazole
go.drugbank.com/drugs/DB11964InvestigationalIlaprazole has been investigated in Helicobacter Infections.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesNirogacestat
go.drugbank.com/drugs/DB12005ApprovedInvestigationalNirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment for desmoid tumors. Desmoid tumors are typically characterized by aberrant activation in Notch signaling. Interaction between the n...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSarecycline
go.drugbank.com/drugs/DB12035ApprovedInvestigationalSarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II ...
Categories: P-glycoprotein inhibitorsIberdomide
go.drugbank.com/drugs/DB12101InvestigationalIberdomide is an orally administered cereblon-modulating protein degrader (CELMoD) used to treat multiple myeloma. It binds cereblon, the substrate-recognition component of an E3 ubiquitin ligase complex, and drives the ubiquitination an...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesDefactinib
go.drugbank.com/drugs/DB12282ApprovedInvestigationalDefactinib is a small molecule kinase inhibitor targeted against focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2), the two members of the FAK family of nonreceptor tyrosine kinases. FAK is important for the integrin-...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inducers